TD Lighthouse Capital Fund

Lighthouse Pharmaceuticals is a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. The company's lead program centers on atuzaginstat (COR388), a small molecule inhibitor of gingipains, which are toxic proteases produced by the bacterium Porphyromonas gingivalis. Lighthouse acquired the rights to this program from Quince Therapeutics (formerly Cortexyme) to continue its clinical development in specific patient populations. By targeting the underlying bacterial drivers of neuroinflammation and neurodegeneration, the company aims to provide a novel therapeutic approach for patients with P. gingivalis-positive Alzheimer's.